Back to discover
Disease

Hypertrophy

Late-stage therapeutic developmentEmerging researchSteady momentum
MeSHHypertrophy
4
Publications
21
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones5View
Results expected 4
Recently completed 1
Activity timeline5

Clinical trials

18 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
21
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

A 12-month, Interventional, Open-label, Phase 4 Study in Europe (SHINE) to Investigate the Course of Synovial Hypertrophy as Detected by Joint Ultrasound and MRI in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis.

Phase 4 · Active, not recruiting · Swedish Orphan Biovitrum

A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy.

Phase 3 · Active, not recruiting · Huons Biopharma

Single-Dose Intraoperative Methadone for Pain Management in Pediatric Tonsillectomy: A Randomized Double Blind Clinical Trial

Phase 4 · Recruiting · Duke University

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Phase 4 · Recruiting · Brigham and Women's Hospital

A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease

Phase 4 · Completed · Hanmi Pharmaceutical Company Limited

A Single-center,Randomized,Open-label,12 Months Study,2 Parallel Group to Compare the Efficacy of Everolimus Combination + Tacrolimus in Regression of Left Ventricular Hypertrophy vs Tacrolimus + MMF in Renal Transplant Patients

Phase 4 · Completed · Edoardo Melilli
Recently completed

Evaluation of Perioperative Usage of Ketorolac on Postoperative Pain Reduction in Pediatric Patients with Adenotonsillectom

Phase 4 · Completed · St. Louis University

A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease

Phase 4 · Completed · Hanmi Pharmaceutical Company Limited

A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase Ⅲ Study to Evaluate the Efficacy and Safety of NABOTA® in Subjects With Benign Masseteric Hypertrophy

Phase 3 · Completed · Daewoong Pharmaceutical Co. LTD.

A Single-center,Randomized,Open-label,12 Months Study,2 Parallel Group to Compare the Efficacy of Everolimus Combination + Tacrolimus in Regression of Left Ventricular Hypertrophy vs Tacrolimus + MMF in Renal Transplant Patients

Phase 4 · Completed · Edoardo Melilli

DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Phase 4 · Completed · University of Dundee

A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN® in Subject With Benign Masseteric Hypertrophy

Phase 3 · Completed · Medy-Tox

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202024
Major themes8
  • Activin Receptors, Type II1
  • Antibodies, Monoclonal, Humanized1
  • Cellular Senescence1
  • Contraceptives, Oral1
  • Disease Susceptibility1
  • Glucagon-Like Peptide-1 Receptor1
  • Glucagon-Like Peptide-1 Receptor Agonists1
  • Menstrual Cycle1
Leading journals4
  • Cells1
  • International journal of molecular sciences1
  • Journal of applied physiology (Bethesda, Md. : 1985)1
  • Molecular metabolism1
Leading researchers8
  • Baur JA1
  • Burke LM1
  • Calhoun R1
  • Colenso-Semple LM1
  • D'Souza AC1
  • Delafontaine P1
  • Drareni K1
  • Elliott-Sale KJ1
Affiliations (unnormalised)6
  • Catholic iPSC Research Center1
  • Heart and Vascular Institute1
  • Institute for Diabetes1
  • Institute of Sport1
  • Mary MacKillop Institute for Health Research1
  • McMaster University1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).

Identifiers
MeSHHypertrophy
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.